How to Cite
Copyright (c) 2023 Ivica Dimitrov, Darko Sazdov
This work is licensed under a Creative Commons Attribution 4.0 International License.
The COVID-19 pandemic, caused by the novel SARS-CoV-2 virus, started in December 2019 in the city Wuhan, province Hubei in the Republic of China. The disease quickly became pandemic and infected 48.539.872 people and had a mortality of 1.232.791 in 215 countries all over the world resulting in economic and healthcare collapse. On 11-th of March the World Health Organisation declared COVID 19 as pandemic. SARS-CoV-2 (severe form of acute respiratory syndrome coronavirus 2) as the cause of COVID 19 is the member of the coronavirus family along with MERS-CoV and SARS-CoV-1which cause severe respiratory infections that are highly contagious and have very high mortality. The pandemic character, the high morbidity and mortality and rehabilitation resulted in a massive vaccine production as an attempt to control the spread of the SARS CoV-2 virus and reduce the morbidity and mortality, especially in the most vulnerable population groups. The aim of the study was to evaluate the association between vaccination status, number of doses and disease severity, length of hospital stay and mortality. Material and Methods: In this case-control study we included 230 male and female patients admitted in the Covid Centre in Acibadem Clinical Hospital in Skopje from March 2021 to February 2022. Patients were divided in two groups according to their vaccination status. Data about patients demographics, comorbidities, vaccination, number of doses received, type of oxygen and ventilation support, length of stay and patient outcome were collected. Results: A total of 230 COVID-19 positive hospitalized patients participated in the study. 50.4% of them were vaccinated, of which 86.2% received two doses, 11.2% received one and 2.6% received three doses of vaccines. A significant association was registered between lethal outcome and vaccination (PearsonChi-square: 5.32523, p=.0210), association with number of doses of vaccination (PearsonChi-square: 7.66262, p=.043524), association with type of ventilation - NIV, HFO, IMV (PearsonChi-square: 177.399, df=3, p=0.000), associationwithcomorbidity (3.90770, p=.0480). Conclusion: Vaccination against Covid-19 and number of doses have a significant impact on disease severity, progression and outcome of the disease.
- Khan M, Adil SF, Alkhathlan HZ, Tahir MN, Saif S, Khan M, Khan ST. COVID-19: A Global Challenge with Old History, Epidemiology and Progress So Far. Molecules. 2020 Dec 23;26(1):39. doi: 10.3390/molecules26010039.
- Jain U. Effect of COVID-19 on the Organs. Cureus 2020;12:e9540. doi: 10.7759/cureus.9540.
- Maximiano Sousa F, Roelens M, Fricker B, Thiabaud A, Iten A, Cusini A,et al. Risk factors for severe outcomes for COVID-19 patients hospitalised in Switzerland during the first pandemic wave, February to August 2020: prospective observational cohort study. Swiss Med Wkly. 2021;151:w20547. doi: 10.4414/smw.2021.20547.
- Mohammed I, Nauman A, Paul P, Ganesan S, Chen KH, Jalil SMS, et al. The efficacy and effectiveness of the COVID-19 vaccines in reducing infection, severity, hospitalization, and mortality: a systematic review. Hum Vaccin Immunother. 2022 Dec 31;18(1):2027160.. doi: 10.1080/21645515.2022.2027160.
- Huang YZ, Kuan CC. Vaccination to reduce severe COVID-19 and mortality in COVID-19 patients: A systematic review and meta-analysis. Eur Rev Med Pharmacol Sci 2022; 26:1770–1776. doi: 10.26355/eurrev_202203_28248.
- Gravelle TB, Phillips JB, Reifler J, Scotto TJ. Estimating the size of “anti-vax” and vaccine hesitant populations in the US, UK, and Canada: Comparative latent class modeling of vaccine attitudes. Hum. Vaccines Immunother 2022; 18:2008214. doi: 10.1080/21645515.2021.2008214.
- World Health Organization. The COVID-19 candidate vaccine landscape (2021). Available at: https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines.
- Food and Drug Administration. COVID-19 Vaccines Authorized for Emergency Use- Pfizer-BioNTech COVID-19 Vaccine. Available at: https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/pfizer-biontech-covid-19-vaccine.
- Food and Drug Administration. COVID-19 Vaccines Authorized for Emergency Use-Moderna COVID-19Vaccine (2020). Available at: https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/moderna-covid-19-vaccine.
- Medicines and Healthcare products Regulatory Agency. UK medicines regulator gives approval for first UK COVID-19 vaccine (2020). Available at: https://www.gov.uk/government/news/uk-medicines-regulator-gives-approval-for-first-uk-covid-19-vaccine
- Medicines and Healthcare products Regulatory Agency. Oxford University/AstraZeneca COVID-19 vaccine approved (2020). Available at:https://www.gov.uk/government/news/oxford-universityastrazeneca-covid-19-vaccine-approved.
- European Medicines Agency. EMA recommends first COVID-19 vaccine for authorisation in the EU (2020).Available at: https://www.ema.europa.eu/en/news/ema-recommends-first-covid-19-vaccine-authorisation-eu.
- Russian Direct Investment Fund. Sputnik V authorized in 26 countries (2021). Available at:https://sputnikvaccine.com/newsroom/pressreleases/sputnik-v-authorized-in-26-countries.
- European Medicines Agency. EMA recommends COVID-19 Vaccine Moderna for authorisation in the EU (2021). Available at: https://www.ema.europa.eu/en/news/ema-recommends-covid-19-vaccine-moderna-authorisation-eu.
- Coronavirus Today. COVID-19 VACCINES (2021). Available at: https://www.coronavirustoday.com/covid-19-vaccines.
- He Q, Mao Q, Zhang J, Bian L, Gao F, Wang J, et al. COVID-19 Vaccines: Current understanding on immunogenicity, safety, and further considerations. Front Immunol 2021;12:669339, doi:10.3389/fimmu.2021.669339
- Fiolet T, Kherabi Y, MacDonald CJ, Ghosn J, Peiffer-Smadja N. Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: a narrative review. Clinical Microbiology and Infection 2022; 28(2):202-21
- Patel MK, Bergeri I, Bresee JS, Cowling BJ, Crowcroft NS, Fahmy K, et al. Evaluation of post-introduction COVID-19 vaccine effectiveness: Summary of interim guidance of the World Health Organization. Vaccine 2021; 39(30):4013-4024. doi: 10.1016/j.vaccine.2021.05.099. .
- Ruiz-Giardin JM, Rivilla M, Mesa N, Morales A, Rivas L, Izquierdo A, et al. FUENCOVID Group. Comparative study of vaccinated and unvaccinated hospitalised patients: A retrospective population study of 500 hospitalised patients with SARS-CoV-2 infection in a spanish population of 220,000 inhabitants. Viruses 2022;14(10):2284. doi: 10.3390/v14102284.
- Papaioannou O, Karampitsakos T, Tsiri P, Sotiropoulou V, Koulousousa E, Tasiopoulos P, et al. Clinical outcomes in vaccinated and unvaccinated patients with COVID-19: a population-based analysis. Eur Rev Med Pharmacol Sci. 2022 Oct;26(20):7705-7712. doi: 10.26355/eurrev_202210_30047
- Grasselli G, Zanella A, Carlesso E, et al. Association of COVID-19 vaccinations with intensive care unit admissions and outcome of critically ill patients with COVID-19 pneumonia in Lombardy, Italy. JAMA Netw Open 2022; 5(10):e2238871. doi:10.1001/jamanetworkopen.2022.38871
- Whittaker R, Bråthen Kristofferson A, Valcarcel Salamanca B, Seppälä E, Golestani K, Kvåle R, et al. Length of hospital stay and risk of intensive care admission and in-hospital death among COVID-19 patients in Norway: a register-based cohort study comparing patients fully vaccinated with an mRNA vaccine to unvaccinated patients. Clin Microbiol Infect 2022; 28(6):871-878.
- Samara AA, Boutlas S, Janho MB, Gourgoulianis KI, Sotiriou S. COVID-19 severity and mortality after vaccination against SARS-CoV-2 in Central Greece. J Pers Med 2022; 12(9):1423. doi: 10.3390/jpm12091423.
- Gao YD, Ding M, Dong X, Zhang JJ, Kursat Azkur A, Azkur D, et al. Risk factors for severe and critically ill COVID-19 patients: A review. Allergy 2021;76(2):428-455. doi: 10.1111/all.14657.
- Dessie ZG, Zewotir T. Mortality-related risk factors of COVID-19: a systematic review and meta-analysis of 42 studies and 423,117 patients. BMC Infect Dis 2021;21(1):855. doi: 10.1186/s12879-021-06536-3.
- Izcovich A, Ragusa MA, Tortosa F, Lavena Marzio MA, Agnoletti C, Bengolea A, et al. Prognostic factors for severity and mortality in patients infected with COVID-19: A systematic review. PLoS One. 2020;15(11):e0241955. doi: 10.1371/journal.pone.0241955.
- Verma M, Sharma S, Kumar A, Hakim A, Bhansali S, Meena R. Comorbidities and vaccination status of COVID-19 all-cause mortality at a tertiary care center of Western India. Cureus. 2022;14(1):e21721. doi: 10.7759/cureus.21721.
- Motos A, López-Gavín A, Riera J, Ceccato A, Fernández-Barat L, Bermejo-Martin JF, et al; CIBERESUCICOVID Project (COV20/00110, ISCIII). Higher frequency of comorbidities in fully vaccinated patients admitted to the ICU due to severe COVID-19: a prospective, multicentre, observational study. Eur Respir J. 2022;59(2):2102275. doi: 10.1183/13993003.02275-2021.
- Brosh-Nissimov T, Orenbuch-Harroch E, Chowers M, Elbaz M, Nesher L, Stein M, et al. BNT162b2 vaccine breakthrough: clinical characteristics of 152 fully vaccinated hospitalized COVID-19 patients in Israel. Clin Microbiol Infect 202127(11):1652-1657. doi: 10.1016/j.cmi.2021.06.036.
- Sieurin J, Brandén G, Magnusson C, Hergens MP, Kosidou K. A population-based cohort study of sex and risk of severe outcomes in covid-19. European Journal of Epidemiology. 2022:1-1.
- Intawong K, Chariyalertsak S, Chalom K, Wonghirundecha T, Kowatcharakul W, Ayood P, et al. Reduction in severity and mortality in COVID-19 patients owing to heterologous third and fourth-dose vaccines during the periods of delta and omicron predominance in Thailand. International Journal of Infectious Diseases. 2023;126:31-8
- Mayr FB, Talisa VB, Shaikh O, Yende S, Butt AA. Effectiveness of homologous or heterologous Covid-19 boosters in veterans. New England Journal of Medicine. 2022; 386(14):1375-7.